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Two Months of Therapy: A Case of Pathologic Complete Response to Chemo-Immunotherapy in a 
Patient with Metastatic Colorectal Cancer 
Introduction: 
Colorectal cancer (CRC) is the fourth most common cancer in the United States (US), and the second 
leading cause of cancer related deaths. In the past decade, targeted therapies have increased the 
median overall survival (mOS) for metastatic CRC from 12 months to 30 months (1). Recent data 
emerging from The Cancer Genome Atlas have identified subtypes of colon cancer associated with 
common oncogenic pathways (2). One area of particular interest involves a subset of CRC with mismatch 
repair deficiency associated with a hypermutated phenotype. This phenotype of CRC potentially results 
from thousands of mutations linked to inherited mismatch repair mechanisms (e.g. Lynch Syndrome) or 
sporadic cancers associated with somatic mutations or epigenetic phenomenon including gene 
promoter methylation leading to silencing of gene expression. Knowledge of the mutations that are 
responsible for CRC biology provides opportunity for developing therapeutic targets. 
Instability of microsatellites, both truncated and expanded, are observed in up to 20% of early stage 
CRCs and up to 5% of advanced stage CRC (3). High microsatellite instability (MSI), is often associated 
with a high mutation burden, in the range of thousands per mega base. MSI cancers increase recognition 
by the cytotoxic T lymphocytes, and carry a better prognosis compared to stable microsatellite tumors 
(4,5). Most CRC cases arising from MMR are secondary to somatic mutations, and the minority arise 
from germline mutations such as Lynch Syndrome (6). The four genes associated with Lynch Syndrome 
are MLH1, MSH2, MSH6 and PMS2. Sporadic deficiencies in MMR result from MLH1 methylation that 
produces complete loss of the MMR pathway (6). Immune surveillance plays a role in CRC regulation, 
and tumor dysregulation of immune checkpoints may contribute to immune resistance mechanisms (7). 
Therapeutic manipulation to promote CRC antitumor immunity has been studied. Two immune 
checkpoint inhibitors, CTLA4 and PD-1 antibodies, increase immune response in CRC tumors with high 
MSI (8). While the majority of patients with advanced CRC do not benefit from single agent immune 
checkpoint inhibitors, phase II studies suggest a disease control rate of 70% in patients treated with 
single agent nivolumab or pembrolizumab (9,10). Pembrolizumab is now approved for patients with 
mismatch repair deficient (dMMR) tumors, irrespective of the site of disease. Immunotherapy for CRC 
could involve 5-fluorouracil (5FU)to enhance anti-tumor immunity via elimination of myeloid derived 
tumor suppressive cells and increased IFN-γ production by tumor specific CD8+ cells. Preclinical studies 
have established the role of chemotherapy as immune modulating agents that could be synergistic with 
immune checkpoint inhibitors in CRC. In mouse models, oxaliplatin has been reported to induce 
immunogenic cell death leading 
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 to release of neoantigens that are engulfed by dendritic cells and presented to tumor-specific 
 CD8+ T cells (11, 12). 
Based on the previously reported data, a clinical trial was designed to evaluate the safety and efficacy of 
mFOLFOX6 (5FU, leucovorin and oxaliplatin) in combination with pembrolizumab in patients with 
advanced, unresectable CRC irrespective of their MMR status. Here we report a complete pathologic 
response in a patient with dMMR CRC who received mFOLFOX6 with pembrolizumab after only 2 
months of therapy as observed at time of surgical resection. 
Discussion/Case: 
A 28 year-old woman presented with diarrhea and hematochezia for several months. Colonoscopy 
demonstrated evidence of a large sigmoid colon mass that was biopsied as poorly differentiated 
adenocarcinoma of the colon. A three generation pedigree with emphasis on cancers and tumors was 
obtained during genetic counselling and revealed her paternal grandfather died from colorectal cancer 
at age 32.  Immunohistochemical stains with working controls were performed on the specimen. Cancer 
cells are strongly and diffusely positive for keratin cocktail and CDX2 with negative staining for CK7, 
CK20, Synaptophysin, chromogranin and PAX-8. Immunohistochemical stains for mismatch repair 
(MMR) proteins MLH1, MSH2, MSH6 and PMS2 were performed with evidence of loss of expression of 
MLH1 and PMS2 and normal expression of MSH2 and MSH6.  Patient had genetic counseling to discuss 
confirmation of Lynch syndrome and recommended her father be tested for MLH1 mutation given 
paternal history of early CRC. 
Further molecular studies showed BRAF V600E wild type and KRAS G12D mutation. Her tumor was 
evaluated by FoundationOneTM with evidence of BRCA2, CDK12, PIK3CA, PTEN, APC, ARID1A, ARID2, 
CIC, CREBBP, FAT1, MLH1, MSH2, SPTA1 and TP53 mutations, along with a high tumor mutation burden 
of 48.71muts/Mb. Despite the retained expression of MSH2 and loss of PMS2 on IHC, the findings from 
FoundationOne
TM
 next generation sequencing identified a mutation in MSH2. The patient had 
radiographic evaluation via positron emission tomography (PET) scan demonstrating evidence of large 
central hepatic mass with extrahepatic extensive lymphadenopathy in the porta hepatis and para-aortic 
region (Image 1). 
She was enrolled on clinical trial NCT02375672 and treated with mFOLFOX6 every 2 weeks and 
pembrolizumab (200 mgIV Q 3 weeks). After 2 months of therapy, she experienced an excellent clinical 
response and partial immune RECIST and RECIST response (Image 2). Operative resection of the tumor 
required rectosigmoidectomy, partial cystectomy, left partial hepatectomy, and portocaval lymph node 
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dissection. Final pathology (Image 3) contained only acellular mucin and complete necrosis with 
associated necrotizing granuloma, clusters of foamy macrophages and microcalcifications present in 
pericolonic region consistent with pathologic complete response. No viable tumor was observed in any 
of the resected samples. Immunohistochemical stains were performed on the resected specimen and 
showed that the lymphoid infiltrate surrounding the necrosis is composed mainly of T cells (positive for 
CD3, CD4 and CD8) with small amount of CD20 positive B cells (Image 4). 
Discussion: 
While mismatch repair deficiency for long was associated with improved survival for patients with early 
stage CRC (4,5), the association with advanced disease suggested of worse outcome. However, this 
phenotype is typically associated with increase tumor infiltrating lymphocytes that is associated with 
improved survival in a subset of patients with advanced CRC (9,10,13,14). It was not until recently where 
the correlation between mutation burden, tumor infiltrating lymphocytes and the response to immune 
checkpoint point has been established for patients with CRC. In fact, the FDA has granted in 5/2017 
approval for the use of pembrolizumab based on the presence of mismatch repair deficiency 
irrespective of the tissue of origin.  Since the use of pembrolizumab is limited to < 5% of all patients with 
advanced incurable CRC, efforts are underway to overcome innate resistance to immunotherapy; one 
approach by combining chemotherapy that can lead to immunogenic cell death and other agents that 
can enhance tumor lymphocyte trafficking (15, 16).   
Both chemotherapy and radiation provoke adaptive immune responses in CRC promoting tumor cell 
death, and current research is examining the benefits of combining current treatments with 
immunotherapy. 5-FU and oxaplatin are thought to aid immune mediated death, and based on this 
thought two trials (NCT02375672, NCT02268825) are studying the combination of FOLFOX and 
prembrolizumab in GI and colon cancers (17). This patient as well as others are still being followed on 
the NCT02375672, and the preliminary results of the study have been reported at ASCO (18).  In a small 
study of 14 chemorefractory patients, a combination of atezolizumab, anti-PD-L1 monoclonal antibody, 
and bevacizmab, VEGF blockade, without chemotherapy demonstrated disease response (7%) or 
stability (64%) (NCT01633970) (17).  Additional CRC studies of chemo-immunotherapy combinations 
include a regimen of bevacizumab and FOLFOX leading to increased inflammatory helper T-cells (19). 
Lastly a combined chemo-immunotherapy trial with FOLFOX, bevcizumab and atezolizumab in treatment 
naive patients has shown 87% of the patients demonstrating response or stable disease (20). Multiple 
other studies are underway examining various chemo-immunotherapy combinations in advanced CRC 
cases (21). 
While responses to single agent PD-1 inhibitors have been reported, and a complete pathologic 
response has been documented after extended course of pembrolizumab (13), our report describes a 
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case of dramatic response to a combination of chemotherapy and pembrolizumab with complete tumor 
necrosis and pathologic response within only 2 months of therapy. While dMMR can explain the benefit 
from pembrolizumab, number of molecular abnormalities could have contributed to massive antigen 
presentation associated with chemotherapy. This in part due to the activity associated with mFOLFOX6 
in first line setting (response rate of ~50%) and the presence of abnormalities in DNA homologous 
recombination repair genes (BRCA2, ARID1A, and ARID2) that may confer sensitivity to platinum based 
therapy.  
 
This case raises number of questions regarding:1- the optimal imaging modality to assess for treatment 
response, 2- the role of chemotherapy to enhance responses to immune checkpoint inhibitors, 
especially to enhance activity in dMMR or to overcome innate resistance in proficient MMR, and finally, 
3- the ideal duration of therapy. Several studies have demonstrated prolonged and sustained responses 
in a subset of patients with melanoma and other solid tumors who discontinued therapy due to variable 
reasons including initial progression that was followed by delayed response. Future studies are needed 
to answer these important questions especially in the light of cost associated with this novel class of 
drugs, and risk of immune mediated toxicity. 
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Image 1: PET/CT scan demonstrating large hepatic mass and large sigmoid colon mass extrahepatic 
extensive lymphadenopathy in the porta hepatis 
Image 2: CT scan after 2 months of therapy showing radiographic response 
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Image 3: A. Partial hepatectomy showing complete necrosis and necrotizing granuloma with no viable 
tumor. B. Rectosigmoid Colon resection showing acellular mucin and complete necrosis, necrotizing 
granuloma, clusters of foamy macrophages. 
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Image 4: Immunohistochemical stains show that the lymphoid infiltrate surrounding the necrosis is 
composed mainly of T cells. Positive for CD3 (A), CD4 (B) and CD8 (C) with small amount of CD20 positive 
B cells (D). 
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